Press Releases

SHANGHAI, and KING OF PRUSSIA, PENNSYLVANIA, October 8, 2020 – WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, announced today the opening of a new process development and testing lab in King of Prussia, Pennsylvania.

WuXi Biologics partnered with Discovery Labs and Integrated Project Services (IPS) to lease and renovate the 33,000-square-foot facility, which will include a development lab and shipping, delivery and storage space. The company has already hired more than 50 highly-skilled employees to work at the facility, with plans to hire at least 50 more in the coming months.

“WuXi Biologics is proud to join King of Prussia’s growing biotech community, and the opportunity this facility provides for closer collaboration with our partners to benefit patients worldwide,” said Dr. Chris Chen, CEO of WuXi Biologics. “Drawing from the talented workforce in the greater Pennsylvania region, we are excited to help both our local and global partners advance their innovative and life-saving ideas.”

The King of Prussia site is the first of three WuXi Biologics facilities in the United States to open for business in response to customer needs. The company recently began construction of a 107,000-square-foot clinical and commercial manufacturing facility in Worcester, Massachusetts, and signed a 10-year lease for a 66,000-square-foot clinical manufacturing facility in Cranbury, New Jersey.

WuXi Biologics commemorated the King of Prussia facility opening with a virtual celebration featuring remarks from company executives, site leaders, local partners and other guests. Representatives from the offices of Senators Bob Casey and Pat Toomey were also in attendance.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. As of June 30, 2020, there were a total of 286 integrated projects, including 141 projects in pre-clinical development stage, 125 projects in early-phase (phase I and II) clinical development, 19 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 280,000 liters after 2023, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit: www.wuxibiologics.com

Media contact

PR@wuxibiologics.com